about
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy.Irinotecan pharmacogenomicsImpacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer.Pharmacogenomics and stomach cancer.Integrating pharmacogenetics into society: in search of a model.Pharmacogenetics of irinotecan toxicity.Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research programPharmacogenetics/genomics and personalized medicine.Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy.Pharmacogenomics: from bedside to clinical practice.Global pharmacogenetics: giving the genome to the masses.The role of drug-metabolising enzymes in clinical responses to chemotherapy.Expressions of Thymidylate Synthase,Thymidine Phosphorylase, Class III β-tubulin, and Excision Repair Cross-complementing Group 1predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or CisplatinPharmacogenomics of colorectal cancer prevention and treatment.Pharmacogenetics and oncology treatment for breast cancer.Impact of pharmacogenomics on clinical practice in oncology.Therapeutic drug monitoring of cancer chemotherapy.Bendamustine as a model for the activity of alkylating agents.Polymorphism of CYP3A4 and ABCB1 genes increase the risk of neuropathy in breast cancer patients treated with paclitaxel and docetaxel.Creating and evaluating genetic tests predictive of drug response.Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer.Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.Association between polymorphisms in XRCC1 gene and treatment outcomes of patients with advanced gastric cancer: a systematic review and meta-analysis.Prognostic significance of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in biliary tract cancer patients receiving adjuvant 5-fluorouracil-based chemotherapy.Oral mucositis: the new paradigms.XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): in silico and in vitro insights.Association of genetic variability in enzymes metabolizing chemotherapeutic agents with treatment response in head and neck cancer cases.Detection of single nucleotide polymorphisms by minisequencing on a polypyrrole DNA chip designed for medical diagnosis.Impact of GSTM1, GSTT1 and GSTP1 gene polymorphism and risk of ARV-associated hepatotoxicity in HIV-infected individuals and its modulation.Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy.A functional polymorphism of SSBP1 gene predicts prognosis and response to chemotherapy in resected gastric cancer patients.Association of GSTT1 polymorphism with acute myeloid leukemia risk is dependent on smoking status.Pharmacogenetic And Tumour Drugs.
P2860
Q27863360-6D25DADA-7EE7-4D81-8674-1D46A0A3C05DQ28287024-98AEB7CE-7DC8-4A6C-8181-5CA76D4977B3Q33317139-53E65001-2DAA-4468-B28C-7FD18A1E5EBBQ33337970-60853D22-7670-4DCE-8041-A49861B8BC5AQ33394505-90037710-46B0-4523-B165-8424826FFC78Q33879736-8D0208F7-D533-4D14-8F86-EA9543C80C24Q35873676-5590DBDA-D810-4920-BE57-EBF7410F4734Q35889615-53FC3FE0-9467-4095-B256-95E1DBF27DADQ35911147-D89F6943-08B5-4BD2-97B9-1D4F499AB8A7Q36117881-FF9880DB-7BAC-4196-9326-8758B556F8F0Q36294685-85367C29-8B98-42D7-AD72-57E23BF983CAQ36301463-61E1F407-9981-410F-96F8-DE01B2413302Q36465177-0B292C17-10FD-41E6-A35E-DDD931E767C7Q36497092-177DC139-8F1F-4563-89E4-FFB11C1B6541Q36545015-BE15AA7F-EFB4-44EA-8402-8ECA6D7E220EQ36551124-0F996FA3-2C72-4106-99C8-523F95F643F6Q36597059-A3220BBE-036B-4706-85F6-74E69024612EQ36719659-EED62A4B-295E-409B-935D-3219267E87DEQ36775605-AD0FC5CA-12B0-4C82-A16C-9BB4D81FB7A9Q37018328-71359ACD-5A40-42DA-B229-94C784EE1290Q37179377-D9F43F36-91B8-4776-9D31-C3F44D5581F2Q37187663-F476C7EF-1079-4910-A81E-8BB5855A8C2AQ37202607-0302A9ED-DF73-47E7-8E2D-1D00C37DFD6BQ37262623-A6F3C608-D5DD-4B77-947E-570BAB01FE18Q37345347-B0C217C9-DBA3-4F59-AACE-098F685CA411Q37499473-0E71374F-5218-4FDA-8B43-FE05DE6A91ECQ37560783-78B96015-4E81-492D-A87E-715126673F7BQ37756485-9E855F51-0335-4C30-87D4-2F5E14E9EEA1Q38072637-2AC6F2F4-E4ED-4C59-B915-AC368D2891D0Q38086603-A43E4C4C-50A7-4796-86A3-841DFFB0F24CQ40080780-D691569A-488B-40B9-94F0-337CCF7EE2A9Q40315024-66E89F1D-42FD-4ED8-A42F-A794BC76B660Q40871154-221AD405-E01F-4CB0-9F03-A98FEC3B5F92Q46553551-AE80D57D-1ADA-4CDB-898C-8896123404CBQ49991976-EB75A3F0-259D-4D0A-820C-606688CCAB91Q53405122-055938CD-E1FB-43D0-8749-9170A9B136F2Q55461722-85758AF8-9637-4D9D-82B3-BBFEA8F94225
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cancer pharmacogenetics.
@ast
Cancer pharmacogenetics.
@en
type
label
Cancer pharmacogenetics.
@ast
Cancer pharmacogenetics.
@en
prefLabel
Cancer pharmacogenetics.
@ast
Cancer pharmacogenetics.
@en
P2860
P921
P356
P1476
Cancer pharmacogenetics.
@en
P2093
P2860
P2888
P356
10.1038/SJ.BJC.6601487
P407
P577
2004-01-01T00:00:00Z
2004-01-12T00:00:00Z